Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Frontiers in Oncology|April 1, 2022
Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple MyelomaFrancesca Bonello, Serena Rocchi, Gregorio Barilà, et al.
Journal of Hematology & Oncology|November 29, 2013
Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicityLaura Quotti Tubi, Carmela Gurrieri, Alessandra Brancalion, et al.
Frontiers in Oncology|July 2, 2021
Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma PatientsGregorio Barilà, Laura Pavan, Susanna Vedovato, et al.
Journal of Translational Medicine|November 30, 2013
The chromatin remodelling component SMARCB1/INI1 influences the metastatic behavior of colorectal cancer through a gene signature mapping to chromosome 22Massimo Pancione, Andrea Remo, Caterina Zanella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2012
Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein responseSabrina Manni, Alessandra Brancalion, Laura Quotti Tubi, et al.
British Journal of Haematology|June 12, 2026
From variant detection to interpretation in idiopathic erythrocytosis: A structured approach applied to a clinical cohortAlessandra Giannella, Fabrizio Vianello, Simone Zoletto, et al.
Annals of Hematology|September 21, 2023
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working GroupGregorio Barilà, Francesca Maria Quaglia, Anna Furlan, et al.
Cancer Medicine|April 1, 2024
A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experienceAnna Furlan, Michele Cea, Laura Pavan, et al.
Frontiers in Oncology|July 10, 2023
Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignanciesFrancesco Angotzi, Marco Petrella, Tamara Berno, et al.
Haematologica|March 19, 2026
A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasoneCarmine Liberatore, Alfonso Piciocchi, Donatella Vincelli, et al.
Pageof 3